Fossati A, Vimercati M G, Bandi G L, Formenti A
Research and Development, Formenti Pharmaceutical Co., Origgio (VA), Italy.
Drugs Exp Clin Res. 1990;16(11):575-9.
It is well known that the nasal route may be an effective alternative to the administration of drugs poorly absorbed via oral administration. Thus an investigation of neostigmine bioavailability after nasal administration was undertaken. The neostigmine kinetic profiles after nasal and intravenous administration in the guinea pig have been compared, and results indicate good nasal absorption of neostigmine. At the same dose, no significant differences have been noticed between the two administration routes, as the area under the curve and the bioavailability index is close to 100%. Moreover nasal administration shows a longer plasmatic elimination compared with the i.v. route (t1/2 beta e.n. = 160.04 min; t1/2 beta i.v. = 23.35 min). Nasal absorption is observed to be dose-related. The present results suggest that nasal administration of neostigmine may be an effective clinical means in Myasthenia gravis therapy.
众所周知,鼻腔给药途径可能是口服吸收不良药物给药的有效替代方法。因此,开展了一项关于新斯的明鼻腔给药后生物利用度的研究。比较了豚鼠鼻腔给药和静脉给药后的新斯的明动力学曲线,结果表明新斯的明鼻腔吸收良好。在相同剂量下,两种给药途径之间未观察到显著差异,因为曲线下面积和生物利用度指数接近100%。此外,与静脉给药途径相比,鼻腔给药显示出更长的血浆消除时间(t1/2β鼻腔给药 = 160.04分钟;t1/2β静脉给药 = 23.35分钟)。观察到鼻腔吸收与剂量相关。目前的结果表明,新斯的明鼻腔给药可能是重症肌无力治疗中的一种有效临床手段。